Ipsen's (EPA:IPN) investors will be pleased with their strong 186% return over the last five years

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But when you pick a company that is really flourishing, you can make more than 100%. Long term Ipsen S.A. (EPA:IPN) shareholders would be well aware of this, since the stock is up 170% in five years. Then again, the 9.5% share price decline hasn't been so fun for shareholders. This could be related to the recent financial results, released recently - you can catch up on the most recent data by reading our company report.

Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for Ipsen

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

During the five years of share price growth, Ipsen moved from a loss to profitability. Sometimes, the start of profitability is a major inflection point that can signal fast earnings growth to come, which in turn justifies very strong share price gains.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
ENXTPA:IPN Earnings Per Share Growth March 11th 2025

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

Advertisement

What About Dividends?

As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Ipsen's TSR for the last 5 years was 186%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

A Different Perspective

It's nice to see that Ipsen shareholders have received a total shareholder return of 4.4% over the last year. Of course, that includes the dividend. Having said that, the five-year TSR of 23% a year, is even better. Potential buyers might understandably feel they've missed the opportunity, but it's always possible business is still firing on all cylinders. It's always interesting to track share price performance over the longer term. But to understand Ipsen better, we need to consider many other factors. Case in point: We've spotted 2 warning signs for Ipsen you should be aware of.

But note: Ipsen may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on French exchanges.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:IPN

Ipsen

A biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide.

Flawless balance sheet with acceptable track record.

Advertisement

Weekly Picks

TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3637.3% undervalued
37 users have followed this narrative
14 users have commented on this narrative
18 users have liked this narrative
MA
CSG logo
Marek_Trnka on CSG ·

Czechoslovak Group - is it really so hot?

Fair Value:€5548.6% undervalued
40 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
AL
alex30free
SECARE logo
alex30free on Swedencare ·

The Compound Effect: From Acquisition to Integration

Fair Value:SEK 46.2846.8% undervalued
11 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

DO
Double_Bubbler
MDAI logo
Double_Bubbler on Spectral AI ·

Spectral AI: First of Its Kind Automated Wound Healing Prediction

Fair Value:US$569.0% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DO
Double_Bubbler
ENSI logo
Double_Bubbler on EnSilica ·

Why EnSilica is Worth Possibly 13x its Current Price

Fair Value:UK£590.1% undervalued
114 users have followed this narrative
17 users have commented on this narrative
0 users have liked this narrative
QU
SOFI logo
Quant_Trader on SoFi Technologies ·

SoFi Technologies will ride a 33% revenue growth wave in the next 5 years

Fair Value:US$39.9851.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.886.3% undervalued
59 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0227.7% undervalued
1072 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2233.5% undervalued
1272 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement